Nourin-Dependent miR-137 and miR-106b: Novel Biomarkers for Early Diagnosis of Myocardial Ischemia in Coronary Artery Disease Patients

Background: Although cardiovascular imaging techniques are widely used to diagnose myocardial ischemia in patients with suspected stable coronary artery disease (CAD), they have limitations related to lack of specificity, sensitivity and “late” diagnosis. Additionally, the absence of a simple laboratory test that can detect myocardial ischemia in CAD patients, has led to many patients being first diagnosed at the time of the development of myocardial infarction. Nourin is an early blood-based biomarker rapidly released within five minutes by “reversible” ischemic myocardium before progressing to necrosis. Recently, we demonstrated that the Nourin-dependent miR-137 (marker of cell damage) and miR-106b-5p (marker of inflammation) can diagnose myocardial ischemia in patients with unstable angina (UA) and also stratify severity of ischemia, with higher expression in acute ST-segment elevation myocardial infarction (STEMI) patients compared to UA patients. Minimal baseline-gene expression levels of Nourin miRNAs were detected in healthy subjects. Objectives: To determine: (1) whether Nourin miRNAs are elevated in chest pain patients with myocardial ischemia suspected of CAD, who also underwent dobutamine stress echocardiography (DSE) or ECG/Treadmill stress test, and (2) whether the elevated levels of serum Nourin miRNAs correlate with results of ECHO/ECG stress test in diagnosing CAD patients. Methods: Serum gene expression levels of miR-137, miR-106b-5p and their corresponding molecular pathway network were measured blindly in 70 enrolled subjects using quantitative real time PCR (qPCR). Blood samples were collected from: (1) patients with chest pain suspected of myocardial ischemia (n = 38) both immediately “pre-stress test” and “post-stress test” 30 min. after test termination; (2) patients with acute STEMI (n = 16) functioned as our positive control; and (3) healthy volunteers (n = 16) who, also, exercised on ECG/Treadmill stress test for Nourin baseline-gene expression levels. Results: (1) strong correlation was observed between Nourin miRNAs serum expression levels and results obtained from ECHO/ECG stress test in diagnosing myocardial ischemia in CAD patients; (2) positive “post-stress test” patients with CAD diagnosis showed upregulation of miR-137 by 572-fold and miR-106b-5p by 122-fold, when compared to negative “post-stress test” patients (p < 0.001); (3) similarly, positive “pre-stress test” CAD patients showed upregulation of miR-137 by 1198-fold and miR-106b-5p by 114-fold, when compared to negative “pre-stress test” patients (p < 0.001); and (4) healthy subjects had minimal baseline-gene expressions of Nourin miRNAs. Conclusions: Nourin-dependent miR-137 and miR-106b-5p are promising novel blood-based biomarkers for early diagnosis of myocardial ischemia in chest pain patients suspected of CAD in outpatient clinics. Early identification of CAD patients, while patients are in the stable state before progressing to infarction, is key to providing crucial diagnostic steps and therapy to limit adverse cardiac events, improve patients’ health outcome and save lives.

[1]  R. Christenson,et al.  Nourin-Associated miRNAs: Novel Inflammatory Monitoring Markers for Cyclocreatine Phosphate Therapy in Heart Failure , 2021, International journal of molecular sciences.

[2]  R. Christenson,et al.  Nourin-Dependent miR-137 and miR-106b: Novel Early Inflammatory Diagnostic Biomarkers for Unstable Angina Patients , 2021, Biomolecules.

[3]  Yao Chen,et al.  Circulating Exosomal miRNAs as Novel Biomarkers for Stable Coronary Artery Disease , 2020, BioMed research international.

[4]  R. Christenson,et al.  Abstract 13051: Nourin-dependent Mirna-137 : A Novel Early Diagnostic Biomarker for Unstable Angina Patients , 2020 .

[5]  R. Poston,et al.  Abstract 13311: Cyclocreatine Phosphate: A Novel Mechanism for Preventing Development of Heart Failure , 2020 .

[6]  R. Christenson,et al.  Abstract 13103: Nourin-dependent Mirna-106b : A Novel Early Inflammatory Diagnostic Biomarker for Cardiac Injury , 2020 .

[7]  V. Sreenivas,et al.  Circulating miR-133b and miR-21: potential non-invasive diagnostic biomarkers of coronary artery disease , 2020 .

[8]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[9]  V. Dilsizian,et al.  Impact of the ISCHEMIA Trial on Stress Nuclear Myocardial Perfusion Imaging , 2020, The Journal of Nuclear Medicine.

[10]  J. Ruidavets,et al.  Identification of a miRNA Based-Signature Associated with Acute Coronary Syndrome: Evidence from the FLORINF Study , 2020, Journal of clinical medicine.

[11]  E. Creemers,et al.  MiR-223-3p and miR-122-5p as circulating biomarkers for plaque instability , 2020, Open Heart.

[12]  E. Giannitsis,et al.  Biomarkers for infarct diagnosis and rapid rule-out/rule-in of acute myocardial infarction , 2020, Herz.

[13]  Lijie Wang,et al.  Noncoding RNAs as Biomarkers for Acute Coronary Syndrome , 2020, BioMed research international.

[14]  A. Kossaify,et al.  Stress Echocardiography: Concept and Criteria, Structure and Steps, Obstacles and Outcomes, Focused Update and Review , 2020, Cardiology research.

[15]  G. Lip,et al.  Diagnosis and risk stratification of chest pain patients in the emergency department: focus on acute coronary syndromes. A position paper of the Acute Cardiovascular Care Association , 2020, European heart journal. Acute cardiovascular care.

[16]  Ting Zhao,et al.  MiR-137-3p exacerbates the ischemia-reperfusion injured cardiomyocyte apoptosis by targeting KLF15 , 2019, Naunyn-Schmiedeberg's Archives of Pharmacology.

[17]  D. Stewart,et al.  Systematic Review of MicroRNA Biomarkers in Acute Coronary Syndrome and Stable Coronary Artery Disease. , 2019, Cardiovascular research.

[18]  R. Poston,et al.  Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion , 2019, Expert review of cardiovascular therapy.

[19]  B. Gersh,et al.  Association Between Stress Testing–Induced Myocardial Ischemia and Clinical Events in Patients With Multivessel Coronary Artery Disease , 2019, JAMA internal medicine.

[20]  G. Heusch Myocardial ischemia: lack of coronary blood flow, myocardial oxygen supply-demand imbalance, or what? , 2019, American journal of physiology. Heart and circulatory physiology.

[21]  H. Baynes,et al.  Circulating microRNAs as possible biomarkers for coronary artery disease: a narrative review , 2019, EJIFCC.

[22]  Xiaoping Zhou,et al.  Diagnostic and prognostic value of biomarkers in acute myocardial infarction , 2019, Postgraduate Medical Journal.

[23]  A. Jaffe,et al.  High‐Sensitivity Cardiac Troponin After Cardiac Stress Test: A Systematic Review and Meta‐Analysis , 2019, Journal of the American Heart Association.

[24]  I. Sahin,et al.  Biomarkers in acute myocardial infarction: current perspectives , 2019, Vascular health and risk management.

[25]  N. Tandon,et al.  Assessment of asymptomatic ischemic heart disease using stress myocardial perfusion imaging in patients with type 2 diabetes mellitus , 2018, Indian heart journal.

[26]  Peifeng Li,et al.  Circulating miRNAs as biomarkers for early diagnosis of coronary artery disease , 2018, Expert opinion on therapeutic patents.

[27]  D. Balanescu,et al.  Limitations of Coronary Computed Tomography Angiography in Predicting Acute Coronary Syndrome in a Low to Intermediate-risk Patient with Chest Pain , 2018, Cureus.

[28]  D. Berman,et al.  Predicting the Benefits of Percutaneous Coronary Intervention on 1-Year Angina and Quality of Life in Stable Ischemic Heart Disease: Risk Models From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) , 2018, Circulation. Cardiovascular quality and outcomes.

[29]  Michael S Marber,et al.  Cardiac troponins: from myocardial infarction to chronic disease , 2017, Cardiovascular research.

[30]  N. Mills,et al.  Cardiac Biomarkers and the Diagnosis of Myocardial Infarction in Women , 2017, Current Cardiology Reports.

[31]  S. A. Elgebaly Nourexal™: A Novel Anti-inflammatory / Antiapoptotic Therapy Against Reperfusion Injury , 2016 .

[32]  G. Levine,et al.  PCI Strategies in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Artery Disease. , 2016, Journal of the American College of Cardiology.

[33]  B. Gersh,et al.  The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge. , 2016, European heart journal.

[34]  Alejandro Lucia,et al.  Epidemiology of coronary heart disease and acute coronary syndrome. , 2016, Annals of translational medicine.

[35]  A. Arbab-Zadeh,et al.  CARDIAC COMPUTED TOMOGRAPHY ( TC VILLINES , SECTION EDITOR ) Cardiac CT vs . Stress Testing in Patients with Suspected Coronary Artery Disease : Review and Expert Recommendations , 2015 .

[36]  H. White,et al.  High‐Sensitivity Cardiac Troponin T in Stable Patients Undergoing Pharmacological Stress Testing , 2015, Clinical cardiology.

[37]  P. Douglas,et al.  A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging The COMPASS Study , 2013, Circulation. Cardiovascular genetics.

[38]  D. Berman,et al.  Temporal trends in the frequency of inducible myocardial ischemia during cardiac stress testing: 1991 to 2009. , 2013, Journal of the American College of Cardiology.

[39]  Ping Xie,et al.  MiR-106b and MiR-15b Modulate Apoptosis and Angiogenesis in Myocardial Infarction , 2012, Cellular Physiology and Biochemistry.

[40]  A. Arbab-Zadeh Stress testing and non-invasive coronary angiography in patients with suspected coronary artery disease: time for a new paradigm , 2012, Heart international.

[41]  Hyuk-Jae Chang,et al.  Comparison of stress perfusion MRI and SPECT for detection of myocardial ischemia in patients with angiographically proven three-vessel coronary artery disease. , 2010, AJR. American journal of roentgenology.

[42]  H. Katus,et al.  Highly sensitive cardiac troponin T values remain constant after brief exercise- or pharmacologic-induced reversible myocardial ischemia. , 2008, Clinical chemistry.

[43]  M. Sabatine,et al.  Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. , 2008, European heart journal.

[44]  A. Jaffe,et al.  Usefulness of detectable levels of troponin, below the 99th percentile of the normal range, as a clue to the presence of underlying coronary artery disease. , 2007, The American journal of cardiology.

[45]  E. Picano,et al.  Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting. , 2001, American heart journal.

[46]  S. Houser,et al.  Cardiac-derived neutrophil chemotactic factors: detection in coronary sinus effluents of patients undergoing myocardial revascularization. , 1992, The Journal of thoracic and cardiovascular surgery.

[47]  F. Forouhar,et al.  Cardiac derived neutrophil chemotactic factors; preliminary biochemical characterization. , 1989, Journal of molecular and cellular cardiology.

[48]  E. V. van Beek,et al.  High-Sensitivity Cardiac Troponin I and the Diagnosis of Coronary Artery Disease in Patients With Suspected Angina Pectoris , 2018, Circulation. Cardiovascular quality and outcomes.

[49]  A. Ibrahim,et al.  Acute myocardial infarction. , 2014, Critical care clinics.